2023
Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER
Kondo T, Vaduganathan V, Hernandez A, Lam C, Inzucchi S, Martinez F, De Boer R, Kosiborod M, Desai A, Kober L, Ponikowski P, Sabatine M, Shah S, Solomon S, Mcmurray J. Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER. European Heart Journal 2023, 44: ehad655.979. DOI: 10.1093/eurheartj/ehad655.979.Peer-Reviewed Original ResearchLeft ventricular ejection fractionSafety of dapagliflozinHeart failureDAPA-HFPrimary outcomeEjection fractionMean baseline LVEFBaseline left ventricular ejection fractionPatient-level pooled analysisBackground clinical characteristicsBenefit of dapagliflozinEfficacy of dapagliflozinElevated natriuretic peptidesNatriuretic peptide levelsEffect of dapagliflozinMineralocorticoid receptor antagonistsVentricular ejection fractionCardiovascular deathClinical characteristicsDiscontinuation ratesStandard careHazard ratioPatient characteristicsNatriuretic peptidePooled analysisEfficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER
Kondo T, Butt J, Curtain J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation Heart Failure 2023, 16: e010898. PMID: 37886880, DOI: 10.1161/circheartfailure.123.010898.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionReduced ejection fractionVentricular ejection fractionPatient-level pooled analysisBenefit of dapagliflozinEjection fractionHeart failureAtrial fibrillationBaseline heart rateSinus rhythmHeart ratePrimary outcomeDAPA-HFCardiovascular deathPooled analysisHR rangeEfficacy of dapagliflozinEffect of dapagliflozinHeart failure phenotypeHigher heart rateCardiovascular eventsHazard ratioHigh riskFailure phenotypePatientsDapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
Ostrominski J, Vaduganathan M, Selvaraj S, Claggett B, Miao Z, Desai A, Jhund P, Kosiborod M, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial. Circulation 2023, 148: 1945-1957. PMID: 37830208, DOI: 10.1161/circulationaha.123.065254.Peer-Reviewed Original ResearchConceptsApparent treatment-resistant hypertensionBaseline blood pressureTreatment-resistant hypertensionVentricular ejection fractionEjection fractionNonresistant hypertensionPrimary outcomeHeart failureBP categoriesHigher left ventricular ejection fractionSystolic baseline blood pressureLeft ventricular ejection fractionRelative treatment benefitSerious adverse eventsKey secondary outcomesRisk of hypotensionWorse kidney functionHigh-risk populationProportion of participantsBaseline BP categoriesGreater absolute reductionCardiometabolic comorbiditiesHypertension groupVascular eventsAdverse eventsContemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF The DELIVER Trial
Peikert A, Bart B, Vaduganathan M, Claggett B, Kulac I, Kosiborod M, Desai A, Jhund P, Lam C, Inzucchi S, Martinez F, de Boer R, Hernandez A, Shah S, Petersson M, Langkilde A, McMurray J, Solomon S, Vardeny O. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF The DELIVER Trial. JACC Heart Failure 2023, 12: 631-644. PMID: 37767674, DOI: 10.1016/j.jchf.2023.09.007.Peer-Reviewed Original ResearchBeta-blocker useLeft ventricular ejection fractionHeart failureEjection fractionPrimary outcomeCardiovascular deathAmerican Heart Association/American CollegeSymptomatic heart failureKey secondary endpointVentricular ejection fractionLatest European SocietyCovariate-adjusted modelsSecondary endpointsPrespecified analysisAdverse eventsAmerica guidelinesComorbidity managementChronotropic responseClinical outcomesClinical eventsSafety outcomesAmerican CollegeHigh riskHFpEFLower riskHeart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER
Butt J, Lu H, Kondo T, Bachus E, de Boer R, Inzucchi S, Jhund P, Kosiborod M, Lam C, Martinez F, Vaduganathan M, Solomon S, McMurray J. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER. European Journal Of Heart Failure 2023, 25: 2078-2090. PMID: 37634087, DOI: 10.1002/ejhf.3000.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseModerate chronic obstructive pulmonary diseaseCOPD statusSafety of dapagliflozinObstructive pulmonary diseaseHeart failurePulmonary diseasePrimary outcomeEjection fractionWorse outcomesKansas City Cardiomyopathy Questionnaire scoreBenefit of dapagliflozinPre-specified analysisSevere pulmonary diseaseCardiovascular deathCause hospitalizationPrimary endpointTreatment discontinuationAdverse eventsClinical eventsQuestionnaire scoresPlaceboDapagliflozinPatientsKnown historyDapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
Chatur S, Vaduganathan M, Claggett B, Mc Causland F, Desai A, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Sabatine M, Kober L, Ponikowski P, Merkely B, Petersson M, Langkilde A, McMurray J, Solomon S. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. Journal Of The American College Of Cardiology 2023, 82: 1854-1863. PMID: 37634707, DOI: 10.1016/j.jacc.2023.08.026.Peer-Reviewed Original ResearchConceptsDeterioration of eGFRHeart failureSafety outcomesKidney functionTreatment groupsTime-updated Cox proportional hazards modelsSodium-glucose cotransporter 2 inhibitorsComorbid chronic kidney diseaseCox proportional hazards modelPrimary composite outcomeChronic kidney diseaseCotransporter 2 inhibitorsEffect of dapagliflozinGlomerular filtration rateProportional hazards modelLives of patientsDAPA-HFDrug discontinuationCardiovascular deathCardiovascular outcomesStudy drugChronic heartComposite outcomeDapagliflozin treatmentPrimary outcomeEfficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure
Kondo T, Wang X, Yang M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Kosiborod M, Desai A, Køber L, Ponikowski P, Sabatine M, Langkilde A, Petersson M, Zaozerska N, Bachus E, Solomon S, McMurray J. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. Journal Of The American College Of Cardiology 2023, 82: 1014-1026. PMID: 37610398, DOI: 10.1016/j.jacc.2023.05.056.Peer-Reviewed Original ResearchConceptsSafety of dapagliflozinHeart failurePrimary outcomeEjection fractionPatient-level pooled analysisBenefit of dapagliflozinEfficacy of dapagliflozinReduced ejection fractionEffect of dapagliflozinDAPA-HFCardiovascular deathClinical characteristicsDiscontinuation ratesPatient characteristicsPooled analysisDapagliflozinPatientsBackground treatmentEvent ratesInhibitor efficacyEfficacyGeographic regionsOutcomesTreatmentPrevious reportsDapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Mc Causland F, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R, Docherty K, Fang J, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Saraiva J, McGrath M, Shah S, Verma S, Langkilde A, Petersson M, McMurray J, Solomon S. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2023, 8: 56-65. PMID: 36326604, PMCID: PMC9634592, DOI: 10.1001/jamacardio.2022.4210.Peer-Reviewed Original ResearchConceptsBaseline kidney functionKidney composite outcomeEffect of dapagliflozinEjection fractionHeart failureKidney outcomesComposite outcomePrimary outcomeKidney functionKidney diseaseSodium-glucose cotransporter 2 inhibitorsBaseline eGFR categoryBaseline kidney diseaseBenefit of dapagliflozinComposite kidney outcomeHeart Failure TrialReduced ejection fractionCotransporter 2 inhibitorsHeart failure eventsGlomerular filtration rateOverall incidence rateOverall event rateLives of patientsTreatment effectsEGFR categories
2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan
Yang M, Butt J, Kondo T, Jering K, Docherty K, Jhund P, de Boer R, Claggett B, Desai A, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Langkilde A, Martinez F, Petersson M, Shah S, Vaduganathan M, Wilderäng U, Solomon S, McMurray J. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal Of Heart Failure 2022, 24: 2307-2319. PMID: 36342375, DOI: 10.1002/ejhf.2722.Peer-Reviewed Original ResearchConceptsAngiotensin receptor neprilysin inhibitorMineralocorticoid receptor antagonistsSafety of dapagliflozinHeart failureEjection fractionPrimary outcomeReceptor antagonistRecent guidelinesSodium-glucose cotransporter 2 inhibitorsLower systolic blood pressureBenefit of dapagliflozinPrior HF hospitalizationSacubitril/valsartanCotransporter 2 inhibitorsEffect of dapagliflozinSystolic blood pressureARNI therapyHF hospitalizationCardiovascular deathAdverse eventsHazard ratioBlood pressureSGLT2 inhibitorsPatientsDapagliflozinRelationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
Yeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.833. DOI: 10.1093/eurheartj/ehac544.833.Peer-Reviewed Original ResearchBaseline ET-1 concentrationET-1 concentrationsBaseline ET-1Benefit of dapagliflozinSerum ET-1Kidney functionEndothelin-1Tertile 3NT-proBNPPrimary outcomeCirculating Endothelin-1DAPA-HF trialEfficacy of dapagliflozinET-1 measurementsHeart Failure TrialReduced ejection fractionWorse functional statusET-1 levelsHeart failure outcomesHeart failure severityHigh-sensitivity troponinDAPA-HFCardiovascular deathEGFR slopeLower eGFROutcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF
Adamson C, Welsh P, Morrow D, Docherty K, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Sattar N, Jhund P, McMurray J. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.913. DOI: 10.1093/eurheartj/ehac544.913.Peer-Reviewed Original ResearchIGFBP-7 levelsAdjusted hazard ratioReduced ejection fractionEffect of dapagliflozinIGFBP-7NT-proBNPPrimary outcomeEjection fractionHeart failureDAPA-HFNYHA classCause mortalityHF eventsHighest thirdCorresponding adjusted hazard ratioMore type 2 diabetesHigh-sensitivity troponin TInsulin-like growth factor binding protein 7Growth factor binding protein 7Adverse HF outcomesBenefit of dapagliflozinDAPA-HF trialEfficacy of dapagliflozinHigher NYHA classNYHA class IIBlood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER
Selvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction DELIVER. JACC Heart Failure 2022, 11: 76-89. PMID: 36599553, DOI: 10.1016/j.jchf.2022.09.002.Peer-Reviewed Original ResearchConceptsSystolic blood pressureBlood pressureHeart failureSBP categoriesEjection fractionPrimary outcomeKansas City Cardiomyopathy Questionnaire total symptom scoreTreatment effectsSodium-glucose cotransporter 2 inhibitorsBaseline systolic blood pressureBlood pressure-lowering effectHigher systolic blood pressureHigher heart failureClass I recommendationCotransporter 2 inhibitorsPressure-lowering effectTotal symptom scoreCardiovascular outcomesAdverse eventsAntihypertensive effectSecondary outcomesStroke riskI recommendationSymptom scoresCardiovascular diseaseInfluence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Myhre P, Vaduganathan M, Claggett B, Miao Z, Jhund P, de Boer R, Hernandez A, Inzucchi S, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Lindholm D, Petersson M, Langkilde A, McMurray J, Solomon S. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JACC Heart Failure 2022, 10: 902-913. PMID: 36114137, DOI: 10.1016/j.jchf.2022.08.007.Peer-Reviewed Original ResearchConceptsNT-proBNP concentrationsBaseline NT-proBNP concentrationHigher NT-proBNP concentrationsNT-proBNP levelsNT-proBNPHeart failureEjection fractionN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideBaseline NT-proBNP levelsHigher NT-proBNP levelsBaseline NT-proBNPEfficacy of dapagliflozinElevated NT-proBNPMedian baseline concentrationNT-proBNP quartilesSafety of dapagliflozinPlacebo-controlled trialPrimary composite outcomeAbsolute risk reductionPrevious clinical trialsGreater absolute benefitCardiovascular deathComposite outcomePrimary outcomeEffects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.Peer-Reviewed Original ResearchDAPA-HF trialReduced ejection fractionEjection fractionCardiovascular deathAsian patientsHF eventsElevated N-terminal pro-B-type natriuretic peptideNew York Heart Association functional class IIN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionSafety of dapagliflozinFunctional class IIEffect of dapagliflozinVentricular ejection fractionDAPA-HFDrug discontinuationHFrEF patientsPrimary endpointAdverse eventsHeart failurePrespecified outcomesPrimary outcomeNatriuretic peptideSame extent
2020
The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF
Dewan P, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF. European Heart Journal 2020, 41: ehaa946.0932. DOI: 10.1093/ehjci/ehaa946.0932.Peer-Reviewed Original ResearchChronic obstructive pulmonary diseaseEffect of dapagliflozinPrimary composite outcomeDAPA-HFHeart failureCV deathPlacebo groupComposite outcomeHazard ratioSodium-glucose cotransporter 2 inhibitorsAdditional effective therapiesReduced ejection fractionCotransporter 2 inhibitorsObstructive pulmonary diseaseCardiovascular deathDapagliflozin groupImportant comorbidityEjection fractionPrimary outcomePulmonary diseaseHF eventsSuboptimal treatmentWorse outcomesEffective therapyReduced risk